Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection
Sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
This PHASE2 trial investigates Hepatitis C, Chronic and is currently completed. Ainos, Inc. (f/k/a Amarillo Biosciences Inc. leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Mar 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- CytoPharm, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .